Fast Antibacterial Susceptibility Testing by Measuring Electron Transfer Metabolism
By LabMedica International staff writers Posted on 07 Dec 2020 |

Image: A recently developed device enables faster testing of antibiotic-resistant bacteria (Photo courtesy of Dr. Seokheun `Sean` Choi)
A recently developed device facilitates bacterial antibiotics susceptibility testing by measuring the effect of these drugs on bacterial electron transfer metabolism.
Since some 2.8 million antibiotic-resistant infections occur annually in the United States with more than 35,000 fatalities, fast and simple antimicrobial susceptibility testing (AST) is urgently required to guide effective antibiotic usages and for monitoring of the antimicrobial resistance rate.
Towards this end, investigators at Binghamton University (NY, USA) established a rapid, quantitative, and high-throughput phenotypic AST by measuring electrons transferred from the interiors of microbial cells to external electrodes. Since the transferred electrons are based on microbial metabolic activities and are inversely proportional to the concentration of potential antibiotics, the changes in electrical outputs can be readily used as a signal to efficiently monitor bacterial growth and antibiotic susceptibility.
For this study, the investigators utilized the common Gram-negative pathogenic bacterium Pseudomonas aeruginosa together with the first-line antibiotic gentamicin. The novel detector had eight sensors printed on a paper surface. The minimum inhibitory concentration (MIC) values generated by the new technique were validated by the gold standard broth microdilution (BMD) method.
Results revealed that the new approach provided quantitative, actionable MIC results within just five hours, as it measured electricity produced by bacterial metabolism instead of the days needed for growth-observation methods.
"To effectively treat the infections, we need to select the right antibiotics with the exact dose for the appropriate duration," said senior author Dr. Seokheun Choi, associate professor of electrical and computer engineering at Binghamton University. "There is a need to develop an antibiotic-susceptibility testing method and offer effective guidelines to treat these infections."
"Although many bacteria are energy-producing, some pathogens do not perform extracellular electron transfer and may not be used directly in our platform. However, various chemical compounds can assist the electron transfer from non-electricity-producing bacteria," said Dr. Choi. "For instance, E. coli cannot transfer electrons from the inside of the cell to the outside, but with the addition of some chemical compounds, they can generate electricity. Now we are working on how to make this technique general to all bacteria cells. We leverage this biochemical event for a new technique to assess the antibiotic effectiveness against bacteria without monitoring the whole bacterial growth. As far as I know, we are the first to demonstrate this technique in a rapid and high-throughput manner by using paper as a substrate."
The new method for determining bacterial antibiotic resistance was published in the November 15, 2020 issue of the journal Biosensors and Bioelectronics.
Related Links:
Binghamton University
Since some 2.8 million antibiotic-resistant infections occur annually in the United States with more than 35,000 fatalities, fast and simple antimicrobial susceptibility testing (AST) is urgently required to guide effective antibiotic usages and for monitoring of the antimicrobial resistance rate.
Towards this end, investigators at Binghamton University (NY, USA) established a rapid, quantitative, and high-throughput phenotypic AST by measuring electrons transferred from the interiors of microbial cells to external electrodes. Since the transferred electrons are based on microbial metabolic activities and are inversely proportional to the concentration of potential antibiotics, the changes in electrical outputs can be readily used as a signal to efficiently monitor bacterial growth and antibiotic susceptibility.
For this study, the investigators utilized the common Gram-negative pathogenic bacterium Pseudomonas aeruginosa together with the first-line antibiotic gentamicin. The novel detector had eight sensors printed on a paper surface. The minimum inhibitory concentration (MIC) values generated by the new technique were validated by the gold standard broth microdilution (BMD) method.
Results revealed that the new approach provided quantitative, actionable MIC results within just five hours, as it measured electricity produced by bacterial metabolism instead of the days needed for growth-observation methods.
"To effectively treat the infections, we need to select the right antibiotics with the exact dose for the appropriate duration," said senior author Dr. Seokheun Choi, associate professor of electrical and computer engineering at Binghamton University. "There is a need to develop an antibiotic-susceptibility testing method and offer effective guidelines to treat these infections."
"Although many bacteria are energy-producing, some pathogens do not perform extracellular electron transfer and may not be used directly in our platform. However, various chemical compounds can assist the electron transfer from non-electricity-producing bacteria," said Dr. Choi. "For instance, E. coli cannot transfer electrons from the inside of the cell to the outside, but with the addition of some chemical compounds, they can generate electricity. Now we are working on how to make this technique general to all bacteria cells. We leverage this biochemical event for a new technique to assess the antibiotic effectiveness against bacteria without monitoring the whole bacterial growth. As far as I know, we are the first to demonstrate this technique in a rapid and high-throughput manner by using paper as a substrate."
The new method for determining bacterial antibiotic resistance was published in the November 15, 2020 issue of the journal Biosensors and Bioelectronics.
Related Links:
Binghamton University
Latest Technology News
- Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
- Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
- Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
- Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
- Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
Channels
Clinical Chemistry
view channelMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read more
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more